Clinical Trial Update: Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether Lactobacillus brevis CD2 can prevent oral mucositis caused by radiotherapy and chemotherapy in head and neck cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• Lactobacillus brevis CD2 (Lactobacillus brevis CD2)

Snippet

Sponsor: S. Andrea Hospital | Conditions: Mucositis | Phase 4 | Status: UNKNOWN